Adimmune (TPE:4142) Marketable Securities: NT$52 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4142 Adimmune Corp TPE:4142
50 GF Score
Price NT$17.05
GF Value NT$25.86
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Adimmune Marketable Securities?

Adimmune TPE:4142 50 Marketable Securities is NT$52 Mil as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 50/100 and a GF Value™ of NT$25.86 (Possible Value Trap). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Adimmune's Marketable Securities for the quarter that ended in Dec. 2025 was NT$52 Mil.

Adimmune's annual Marketable Securities increased from Dec. 2023 (NT$28 Mil) to Dec. 2024 (NT$128 Mil) but then declined from Dec. 2024 (NT$128 Mil) to Dec. 2025 (NT$52 Mil).

Adimmune  (TPE:4142) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Adimmune Marketable Securities Related Terms

Adimmune Marketable Securities Historical Data

* Premium members only.

The historical data trend for Adimmune's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune Marketable Securities Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 239.00 115.51 27.51 127.51 52.48

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.51 127.51 45.51 45.51 52.48
TPE:4142
50GF Score
Adimmune Corp TPE:4142
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$52 Mil mean?
Adimmune (TPE:4142) has a Marketable Securities of NT$52 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Adimmune and its competitors.
Is Adimmune's Marketable Securities too high?
Adimmune's current Marketable Securities is NT$52 Mil. Overall, Adimmune has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Marketable Securities compare to VRTX and REGN?
Adimmune's Marketable Securities of NT$52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Adimmune and its competitors. Adimmune's current Marketable Securities is NT$52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.86, compared to a current price of NT$17.05 — trading 34.1% below its estimated fair value. The current Marketable Securities is NT$52 Mil. Adimmune's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Marketable Securities is NT$52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$17.05 is trading 34.1% below its estimated GF Value™ of NT$25.86. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • Marketable Securities: NT$52 Mil
  • GF Value™: NT$25.86 vs. price of NT$17.05 (34.1% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
50GF Score

Get the complete analysis for TPE:4142

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.05
Price
NT$25.86
GF Value